Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
AGN [NYSE]
Allergan Inc.
IndexS&P 500 P/E38.49 EPS (ttm)4.37 Insider Own0.10% Shs Outstand297.18M Perf Week-0.61%
Market Cap49.99B Forward P/E20.43 EPS next Y8.23 Insider Trans5.32% Shs Float296.61M Perf Month3.11%
Income1.32B PEG2.26 EPS next Q1.47 Inst Own93.70% Short Float1.35% Perf Quarter1.78%
Sales6.75B P/S7.40 EPS this Y17.60% Inst Trans2.24% Short Ratio2.09 Perf Half Y34.60%
Book/sh22.80 P/B7.38 EPS next Y41.99% ROA11.90% Target Price200.60 Perf Year84.72%
Cash/sh12.50 P/C13.45 EPS next 5Y17.00% ROE19.50% 52W Range88.23 - 174.49 Perf YTD51.58%
Dividend0.20 P/FCF34.96 EPS past 5Y17.90% ROI15.70% 52W High-3.60% Beta0.75
Dividend %0.12% Quick Ratio3.80 Sales past 5Y7.40% Gross Margin87.80% 52W Low90.65% ATR2.97
Employees11700 Current Ratio4.10 Sales Q/Q16.70% Oper. Margin30.60% RSI (14)53.02 Volatility1.38% 1.62%
OptionableYes Debt/Eq0.32 EPS Q/Q17.10% Profit Margin18.70% Rel Volume1.00 Prev Close169.97
ShortableYes LT Debt/Eq0.31 EarningsOct 27 BMO Payout4.60% Avg Volume1.92M Price168.21
Recom1.80 SMA201.11% SMA502.16% SMA20017.96% Volume1,925,800 Change-1.04%
22-Jul-14Upgrade UBS Neutral → Buy $180 → $200
28-Apr-14Downgrade Stifel Buy → Hold
22-Apr-14Downgrade Argus Buy → Hold
07-Mar-14Reiterated Barclays Equal Weight $95 → $130
07-Feb-14Reiterated Argus Buy $110 → $130
08-Jan-14Reiterated Argus Buy $110 → $125
07-Jan-14Initiated RBC Capital Mkts Outperform $131
20-Dec-13Reiterated UBS Buy $100 → $116
20-Dec-13Reiterated BMO Capital Markets Outperform $112 → $117
31-Oct-13Reiterated Argus Buy $118 → $110
25-Jun-13Reiterated Canaccord Genuity Hold $111 → $98
24-Jun-13Downgrade Deutsche Bank Buy → Hold
02-May-13Reiterated RBC Capital Mkts Outperform $123 → $119
06-Feb-13Reiterated Stifel Nicolaus Buy $110 → $118
06-Feb-13Reiterated Canaccord Genuity Hold $102 → $111
22-Jan-13Reiterated Canaccord Genuity Hold $101 → $102
19-Sep-12Initiated Canaccord Genuity Hold $101
30-Mar-12Reiterated RBC Capital Mkts Outperform $93 → $106
29-Mar-12Reiterated UBS Buy $100 → $107
29-Mar-12Reiterated Stifel Nicolaus Buy $90 → $110
18-Sep-14 04:15PM  Bayer/Orion Progress with Prostate Cancer Drug ODM-201 Zacks
04:05PM  Allergan-Valeant Fight Holds Lessons for All Corporate Shareholders at New York Times
03:55PM  Merck Enters into Licensing Agreement with Sun Pharma Zacks
01:19PM  Valeant's Improving Stock Price Makes its Allergan Bid Look Better at The Wall Street Journal
17-Sep-14 06:07PM  Auxilium Mulls Endo Bid; Is $2.2 Billion Enough? at Investor's Business Daily
05:10PM  Novo Nordisk's Tresiba Effective in Children & Adolescents Zacks
12:04PM  Valeants Last Shot to Woo Owners of Botox Maker Allergan at New York Times
11:47AM  Auxilium Mulls Endo Bid; Street Eyes A Higher Price at Investor's Business Daily
09:41AM  Faber Report: Dollar General's advance rejected again CNBC
08:28AM  Why Salix Pharmaceuticals (SLXP) Stock Is Higher Today at TheStreet
16-Sep-14 06:53PM  Valeant, Allergan settle suit Investor's Business Daily
05:10PM  Roche Starts Trials on Lampalizumab for Geographic Atrophy Zacks
04:20PM  AstraZeneca and Eli Lilly Collaborate for Alzheimer's Drug Zacks
03:12PM  Allergan reaches truce with suitors on special shareholder meeting Reuters
01:09PM  Why It's Time for Allergan Shareholders to Take Some Profits at TheStreet
12:46PM  This is what Allergan's move to allow meeting on Valeant takeover means at MarketWatch
11:57AM  Allergan, Pershing Square Settle: Now What? at Barrons.com
11:36AM  Video: Valeant, Allergan Settle Suit, Allow Shareholder Vote at Investor's Business Daily
11:36AM  Valeant, Allergan Settle Suit, Allow Shareholder Vote at Investor's Business Daily
09:42AM  Faber Report: Allergan special meeting CNBC
08:34AM  Tigers Chopra Stumbles in Rise to Top Robertson Empire Bloomberg
07:18AM  Allergan agrees to move forward with meeting AP
06:35AM  Allergan agrees to move forward with meeting AP
03:26AM  Allergan reaches truce with suitors on special shareholder meeting Reuters
01:39AM  Pershing Square, Valeant and Allergan Settle Pending Litigation Before the Delaware Court of Chancery Business Wire
12:57AM  Botox Maker Allergan Agrees to Hold Meeting That Could Lead to Takeover at New York Times
12:57AM  Allergan Agrees to Hold Meeting That Could Lead to Takeover at New York Times
12:51AM  Allergan in Agreement on Dec. 18 Meeting at Bloomberg
12:28AM  Allergan, suitors agree to hold special shareholder meeting on Dec. 18 Reuters
12:14AM  [$$] Pershing Square and Allergan Reach Settlement on Litigation Over Special Meeting Date at The Wall Street Journal
15-Sep-14 11:36PM  Allergan to Hold Special Meeting of Stockholders on Originally Scheduled Date of December 18 without Restriction Business Wire
11:30PM  [$$] Pershing Square and Allergan Near Settlement on Litigation Over Special Meeting Date at The Wall Street Journal
08:03PM  Tigers Chopra Stumbles in Rise to Top Robertson Empire at Bloomberg
05:45PM  Big year for Ackman CNBC
04:35PM  Novartis Presents Positive Data on Lucentis and Jetrea Zacks
12:48PM  Ackman goes to Amsterdam CNBC
12:48PM  [video] Ackman goes to Amsterdam at CNBC
12:22PM  Ackman's New Fund Could Spur More Market Activism at Investor's Business Daily
11:55AM  Pershing Square Submits Additional Special Meeting Requests Business Wire
11:21AM  Judge to decide if Ackman can vote shares in Allergan takeover battle at MarketWatch
04:24AM  Ackmans Pershing Fund Seeks to Raise $2 Billion in IPO at Bloomberg
12:00AM  Latisse Appeal, Scottish Web: Intellectual Property at Bloomberg
12-Sep-14 05:10PM  Judge to decide if Ackman can vote shares in Allergan takeover battle at MarketWatch
04:25PM  Will Allergan's Board Be Revamped to Aid Valeant Buyout? Zacks
12:20PM  Midday movers: eBay, Sprint, Yahoo & more at CNBC
10:05AM  UPDATE 4-Allergan investors owning 35 pct to demand special meeting Reuters
09:20AM  [$$] Pershing Touts More Support for Allergan Special Meeting at The Wall Street Journal
08:40AM  [$$] Pershing Touts More Support for Allergan Special Meeting at The Wall Street Journal
08:00AM  Pershing Square Submits Additional Special Meeting Requests Representing 35% of Allergan Shares Business Wire
11-Sep-14 10:38PM  Allergan investors owning 35 pct to demand special meeting Reuters
08:46PM  Allergan Comments On Pershing Square's Delivery Of Additional Requests From Stockholders Owning 1.5% Of Allergan's Shares Benzinga
08:30PM  Allergan Comments on Pershing Square's Delivery of Additional Requests from Stockholders Owning 1.5% of Allergans Shares Business Wire
05:45PM  Eli Lilly/Boehringer's Insulin Biosimilar Gains EU Approval Zacks
02:14PM  Allergan investors owning 35 pct to demand special meeting -sources Reuters
11:28AM  Allergan investors owning 35 pct to demand special meeting -sources Reuters
11:05AM  Allergan vs. Valeant: Where's Perry Mason When You Need Him? at Barrons.com
10:32AM  Allergan investors owning 35 pct to demand special meeting -sources Reuters
10:03AM  Allergan investors owning 35 pct to demand special meeting-sources Reuters
09:38AM  [video] Faber Report: Valeant submits consents at CNBC
10-Sep-14 03:35PM  Auxilium Pharmaceuticals to Restructure, Cut Jobs by 30% Zacks
11:56AM  Bill Ackman Rips Allergan, Inc. In Letter Benzinga
07:40AM  Early movers: AAPL, TWTR, FDO, DG, MSFT, LE & more at CNBC
09-Sep-14 04:56PM  Ackman urges Allergan board to 'wake up' on Valeant talks Reuters
04:30PM  Alexion's Asfotase Alfa Gets Japanese Orphan Drug Status Zacks
03:48PM  In Letter to Botox Maker, Ackman Attacks Board Inaction on Merger Talks at New York Times
03:09PM  Allergan likely to lose bid to stop takeover by Valeant, analyst says at Los Angeles Times
08-Sep-14 04:35PM  Prana Biotechnology Up on Orphan Drug Status for PBT2 Zacks
04:05PM  Novartis (NVS) Presents Positive Data on Ultibro Breezhaler Zacks
03:45PM  Bayer/Regeneron Looking for Eylea Label Expansion in Japan Zacks
06:30AM  Why Valeant's Hostile Takeover Bid of Allergan Is Bad for Shareholders at TheStreet
05-Sep-14 03:16PM  Stocks Rise, Turn Positive Going Into Final Hour at Investor's Business Daily
10:37AM  Allergan OKs Special Shareholder Meeting Consents at TheStreet
10:20AM  Merck's Anti-PD-1 Drug Keytruda First to be Launched in US Zacks
04-Sep-14 07:28PM  [$$] Allergan Approves Special-Meeting Requests at The Wall Street Journal
07:10PM  Allergan Provides Update on Written Requests from Pershing Square Regarding Special Meeting of Stockholders Business Wire
04:10PM  Will AbbVie's $805 Million Agreement for Duvelisib Pay Off? Zacks
01:00PM  Paulson & Co. opens a new key position in Hillshire Brands Market Realist
12:45PM  Midday movers: Allergan, BP, Tesla Motors & more at CNBC
09:41AM  [video] Faber Report: Allergan special meeting coming at CNBC
09:33AM  10 Stocks Billionaire John Paulson Loves in 2014 at TheStreet
03-Sep-14 05:56PM  Paulson & Co. starts a new position in DIRECTV in Q2 2014 Market Realist
05:40PM  Sanofi Reports Positive Phase III Data on Dengue Vaccine Zacks
01:56PM  John Paulson & Co. add a significant new position in Allergan Market Realist
09:56AM  Highlights of Paulson & Co.s important positions in 2Q14 Market Realist
02-Sep-14 02:40PM  Glaxo Up on Accelerated Ebola Vaccine Development Process Zacks
01:33PM  U.S. court revives Botox-linked shareholder suit against Allergan Reuters
12:06PM  U.S. court revives shareholder lawsuit vs. Allergan over Botox Reuters
09:01AM  Allergan Files Answer in Federal Court Responding to Valeant and Pershing Squares Counterclaims Business Wire
08:00AM  Allergan Announces OZURDEX┬« (dexamethasone 700 mcg intravitreal implant in applicator) Now Approved in the European Union for the Treatment of Diabetic Macular Edema Business Wire
28-Aug-14 03:40PM  Allergan Seeks Court Order to Stop Valeant, Affiliates Zacks
06:53AM  [video] Legal Victory for Ackman and Valeant Pharma at Bloomberg
12:00AM  Allergan Attempts to Elude Ackman Bid Fuel Bearish Bets at Bloomberg
27-Aug-14 02:52PM  Valeant, Ackman get Oct. 6 trial over Allergan special meeting Reuters
02:48PM  Allergan sets date for special shareholder meeting AP
02:19PM  Valeant, Ackman get October 6 trial over Allergan special meeting Reuters
02:13PM  Valeant, Ackman get Oct. 6 trial over Allergan special meeting Reuters
01:22PM  Allergan v Valeant: When Will It End? at Barrons.com
12:35PM  Valeant, Ackman Win Bid to Fast-Track Allergan Case at Bloomberg
12:15PM  Valeant, Ackman get October 6 trial over Allergan special meeting Reuters
12:08PM  Valeant, Ackman get Oct. 6 trial over Allergan special meeting Reuters
Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; and facial aesthetics products. The company also holds LiRIS Program, which is in Phase II trials for the treatment of interstitial cystitis/bladder pain syndrome. It sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. The company focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, urogynecologists, and general practitioners. It has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sherman Scott DExecutive Vice President, HRApr 22Option Exercise75.5810,000755,80018,223Apr 23 07:25 PM
Sherman Scott DExecutive Vice President, HRApr 22Sale163.0010,0001,630,0008,223Apr 23 07:25 PM
Sherman Scott DExecutive Vice President, HRApr 21Option Exercise73.044,500328,68012,723Apr 23 07:25 PM
Sherman Scott DExecutive Vice President, HRApr 21Sale139.854,500629,3258,223Apr 23 07:25 PM
LAVIGNE LOUIS J JRDirectorFeb 21Sale125.795,400679,2440Feb 24 07:59 PM
INGRAM DOUGLAS SPresidentFeb 21Sale125.701961,044Feb 25 05:49 PM
Diradoorian Raymond HEVPGlobal Technical OperationsFeb 19Option Exercise58.5523,0001,346,65029,401Feb 21 04:56 PM
EDWARDS JEFFREY LEVP, Fin & Bus. Dev., CFOFeb 19Option Exercise40.1638,9001,562,22455,491Feb 21 04:59 PM
HUDSON DAWN EDirectorFeb 19Sale126.354,200530,68311,600Feb 21 05:14 PM
EDWARDS JEFFREY LEVP, Fin & Bus. Dev., CFOFeb 19Sale126.3938,9004,916,49316,591Feb 21 04:59 PM
Diradoorian Raymond HEVPGlobal Technical OperationsFeb 19Sale126.6623,0002,913,1116,401Feb 21 04:56 PM
Sherman Scott DExecutive Vice President, HRFeb 18Option Exercise75.585,000377,90013,220Feb 19 02:44 PM
Sherman Scott DExecutive Vice President, HRFeb 18Sale125.745,000628,7008,220Feb 19 02:44 PM
INGRAM DOUGLAS SPresidentFeb 14Option Exercise55.9884,0004,701,90085,058Feb 19 02:41 PM
Sherman Scott DExecutive Vice President, HRFeb 14Sale124.761708,220Feb 19 02:44 PM
INGRAM DOUGLAS SPresidentFeb 14Sale124.4084,00010,449,4321,058Feb 19 02:41 PM
PYOTT DAVID E IChairman of the Board and CEOFeb 12Option Exercise36.15252,0009,109,800417,000Feb 13 05:49 PM
BARLOW JAMES FSR. VP, Corp. Controller (PAO)Feb 12Option Exercise65.9223,8751,573,76930,754Feb 13 05:54 PM
PYOTT DAVID E IChairman of the Board and CEOFeb 12Sale123.12252,00031,025,560165,000Feb 13 05:49 PM
BARLOW JAMES FSR. VP, Corp. Controller (PAO)Feb 12Sale123.5223,8752,949,0416,879Feb 13 05:54 PM
Diradoorian Raymond HEVPGlobal Technical OperationsFeb 11Option Exercise55.9817,000951,57523,401Feb 13 05:56 PM
LAVIGNE LOUIS J JRDirectorFeb 11Option Exercise55.2054,6003,014,01924,123Feb 13 05:59 PM
Diradoorian Raymond HEVPGlobal Technical OperationsFeb 11Sale121.8217,0002,070,9576,401Feb 13 05:56 PM
LAVIGNE LOUIS J JRDirectorFeb 11Sale122.3954,6006,682,69612,723Feb 13 05:59 PM
Sherman Scott DExecutive Vice President, HRFeb 10Option Exercise75.585,000377,90013,325Feb 11 08:41 PM
Sherman Scott DExecutive Vice President, HRFeb 10Sale120.005,000600,0008,325Feb 11 08:41 PM
EDWARDS JEFFREY LEVP, Fin & Bus. Dev., CFOFeb 07Option Exercise64.47105,5006,801,585122,371Feb 11 08:37 PM
Sherman Scott DExecutive Vice President, HRFeb 07Option Exercise73.044,500328,68012,825Feb 11 08:41 PM
EDWARDS JEFFREY LEVP, Fin & Bus. Dev., CFOFeb 07Sale117.74105,50012,421,04316,871Feb 11 08:37 PM
Sherman Scott DExecutive Vice President, HRFeb 07Sale118.554,500533,4848,325Feb 11 08:41 PM
Whitcup Scott MExecutive VP, R&D, CSOJan 14Option Exercise55.9842,0002,350,95059,327Jan 15 06:24 PM
Whitcup Scott MExecutive VP, R&D, CSOJan 14Sale117.8042,0004,947,60017,327Jan 15 06:24 PM
Whitcup Scott MExecutive VP, R&D, CSOJan 08Option Exercise55.9842,0002,350,95059,327Jan 10 06:37 PM
Whitcup Scott MExecutive VP, R&D, CSOJan 08Sale113.8042,0004,779,60017,327Jan 10 06:37 PM
Gangolli Julian SCVP & Pres, North AmericaDec 27Option Exercise53.7152,5002,819,77545,547Dec 30 05:18 PM
Gangolli Julian SCVP & Pres, North AmericaDec 27Sale110.0552,5005,777,5508,047Dec 30 05:18 PM
Whitcup Scott MExecutive VP, R&D, CSODec 20Option Exercise36.1533,0001,192,95033,827Dec 20 07:41 PM
Whitcup Scott MExecutive VP, R&D, CSODec 20Option Exercise0.0033,000033,827Jan 06 06:27 PM
Whitcup Scott MExecutive VP, R&D, CSODec 20Sale108.8033,0003,590,40017,327Jan 06 06:27 PM
Whitcup Scott MExecutive VP, R&D, CSODec 20Sale108.8033,0003,590,40017,327Dec 20 07:41 PM
HUDSON DAWN EDirectorNov 27Sale97.463,000292,38215,800Dec 02 04:52 PM
Jones Trevor MDirectorOct 15Option Exercise51.721,00051,7159,142Oct 16 04:54 PM
Jones Trevor MDirectorOct 15Sale90.142,000180,2807,142Oct 16 04:54 PM